Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 18/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 17/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.41 |
| ▸ | PDE4A | P27815 | 2/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7341594 | 0.79 | PDE3B (0.66) | PDE3APDE3BPDE4BPDE4APDE4C | |
| SCHEMBL7350623 | 0.79 | PDE3B (0.66) | PDE3APDE3BPDE4BPDE4APDE4C | |
| SCHEMBL2071896 | 0.78 | PDE3B (1.00) | PDE3APDE3BPDE4BPDE4APDE4C | |
| SCHEMBL7347277 | 0.77 | PDE3B (1.00) | PDE3APDE3BPDE4BPDE4APDE4C | |
| SCHEMBL7341535 | 0.72 | PDE3B (1.00) | PDE3APDE3BPDE4BPDE4APDE4C | |
| SCHEMBL10267004 | 0.69 | PDE3B (0.52) | PDE3APDE3BPDE4D | |
| SCHEMBL20278399 | 0.69 | PDE3B (0.52) | PDE3APDE3BPDE4D | |
| SCHEMBL7350099 | 0.69 | PDE3A (0.53) | PDE3APDE3BPDE4BPDE4APDE4C | |
| SCHEMBL7343962 | 0.68 | PDE3B (0.68) | PDE3APDE3BPDE4D | |
| SCHEMBL422356 | 0.67 | PDE3B (0.50) | PDE3APDE3BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2522670-A1 | Heterocyclic CRF receptor antagonists | Takeda Pharmaceutical Company Limited (JP) | 2012-11-14 | — | — | EP | claimed |
| JP-4790703-B2 | — | — | 2011-10-12 | — | — | JP | claimed |
| EP-1732541-A4 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2008-03-05 | — | — | EP | claimed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | claimed |
| EP-1732541-A2 | CYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2006-12-20 | — | — | EP | claimed |
| WO-2005099688-A2 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-27 | — | — | WO | claimed |
| EP-0272914-A2 | 6-Benzoxazinyl- and 6-benzothiazinyl-2,3,4,5-tetrahydropyridazin-3-ones | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-06-29 | — | — | EP | claimed |
| US-4721784-A | MUSCLE RELAXANTS, BRONCHODILATOR AGENTS, CARDIOTONIC AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-01-26 | — | — | US | claimed |
| EP-2522670-A1 | Heterocyclic CRF receptor antagonists | Takeda Pharmaceutical Company Limited (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7897607-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | disclosed |
| US-5081242-A | Cardiotonic and bronchodilator agents; phosphodiesterase inhibitors | ORTHO PHARMACEUTICAL CORPORATION (US) | 1992-01-14 | — | — | US | disclosed |
| US-4766118-A | CARDIOTONIC AGENTS, PHOSPHODIESTERASE INHIBITORS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-08-23 | — | — | US | disclosed |
| EP-0272914-A2 | 6-Benzoxazinyl- and 6-benzothiazinyl-2,3,4,5-tetrahydropyridazin-3-ones | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-06-29 | — | — | EP | disclosed |
| US-4721784-A | MUSCLE RELAXANTS, BRONCHODILATOR AGENTS, CARDIOTONIC AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179165-A1 | Cyclic compounds | CRHR1, CRHR2, MC2R | PDE3A 1060/4885PDE3B 937/4885PDE4B 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.